PSI CRO

PSI ended 2025 with an exciting expansion in Canada. In addition to a larger office in Toronto, we also welcomed David Allen as the new Canada country manager. Learn more about David and the new office here: bit.ly/3L53bqD

Hard-to-enroll critical care ID trial? PSI helped a biopharma enroll 23% faster than industry norms thanks to strong site communication and trust. Read the story: bit.ly/48HIqJs

As radiopharma therapy continues to evolve, understanding the landscape for running your trials is crucial for success. Watch the webinar with Dylan Stoy, Director, Therapeutic Strategy, Radioligand Therapy (RLT), on demand now: bit.ly/4pXxnTz #radiopharma #CRO

PSI ended 2025 with an exciting expansion in Canada. In addition to a larger office in Toronto, we also welcomed David Allen as the new Canada country manager. Learn more about David and the new office here: bit.ly/3L53bqD

Learn how PSI focused on selecting the right countries and sites to secure full enrollment in under two years for this complex phase 3 DLBCL combination program. Read the full story here: bit.ly/4pLkYCC

When the sponsor of a phase 3 DLBCL combination treatment needed to win the race to market, they engaged PSI to deliver an aggressive recruitment plan amidst a rapidly evolving SoC landscape. Learn how: bit.ly/4pLhLmy

Every sponsor's dream is pivotal trial planning with total confidence. Learn how one AI-powered platform can take the guesswork out of financial and clinical feasibility planning in our latest webinar, now available on demand: bit.ly/4oRrPsS

Sponsors advancing hemophilia gene therapies face rare patient populations, intensive visit schedules, and complex dosing and lab demands. Learn how this sponsor's resilience led to the approval of a life-changing hemophilia treatment: bit.ly/3Y7lm29

"Hematology is moving from incremental improvement to paradigm-level change." – Kasia Moscicka, Head of Feasibility and Site ID, PSI Discover the trends with the most potential to impact the hematology landscape in 2026: bit.ly/4aWz5jG

Sponsors advancing hemophilia gene therapies face rare patient populations, intensive visit schedules, and complex dosing and lab demands. Learn how this sponsor's resilience led to the approval of a life-changing hemophilia treatment: bit.ly/3Y7lm29

Hard-to-enroll critical care ID trial? PSI helped a biopharma enroll 23% faster than industry norms thanks to strong site communication and trust. Read the story: bit.ly/48HIqJs

As radiopharma therapy continues to evolve, understanding the landscape for running your trials is crucial for success. Watch the webinar with Dylan Stoy, Director, Therapeutic Strategy, Radioligand Therapy (RLT), on demand now: bit.ly/4pXxnTz #radiopharma #CRO

When the sponsor of a phase 3 DLBCL combination treatment needed to win the race to market, they engaged PSI to deliver an aggressive recruitment plan amidst a rapidly evolving SoC landscape. Learn how: bit.ly/4pLhLmy

Frost & Sullivan has named PSI a 2025 Enabling Technology Leader in the Best Practices Awards for our "robust commitment to innovation," including the purpose-built, cloud-based INTELIA™ platform. Learn how INTELIA™ drives on-time delivery for sponsors: bit.ly/4mL1CM1

Choosing the right CRO can mean the difference between sleepless nights and the peace of mind that comes with enrolling on time and on budget. Josh Martino of Kumquat Biosciences shares more about his experience finding the right partner in this video. bit.ly/4lfScXI

Choosing the right CRO can mean the difference between sleepless nights and the peace of mind that comes with enrolling on time and on budget. Josh Martino of Kumquat Biosciences shares more about his experience finding the right partner in this video. bit.ly/4lfScXI

Solid site relationships are the backbone of successful clinical trials, built by fostering meaningful, long-term site relationships. Meet our team at #CTOEastCoast to discover how PSI enrolls patients up to 20% faster than the industry: bit.ly/4k0tPN7

SNMMI 2025 kicks off soon! Stop by Booth #1145 to meet PSI’s radiopharm experts and learn how our proven experience and operational strength help deliver complex trials on time and with confidence. Book time with our team now! bit.ly/3SxzU8c

With more than 4,000 sites in our global network, 93% of PSI’s oncology studies meet or beat projected enrollment timelines, helping us prioritize your study. Join us at #CTOEastCoast to learn how PSI can support your trial: bit.ly/4ksmW84

Final countdown to EHA 2025! Stop by Booth #2 in Milan to learn how PSI makes every patient count with on-time project delivery, operational excellence, and a 95% repeat and referral rate. bit.ly/3YJEtzY